Dr John Reed

FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...

News Wire ~ 3rd Party Press Release - 2020/05/28

Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

News Wire ~ 3rd Party Press Release - 2019/03/12

Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.

Established in 2011, SnackSafely.com provides straightforward, actionable information to help improve the lives of the estimated 32 million people in the US suffering with food allergies.

We strive to eliminate anaphylaxis by leveraging our on-line properties to educate, advocate, and connect the allergic community with products and services that help toward achieving this goal.

Our blog covers topics of interest to the food allergy community including news reports; ongoing research, clinical studies, trials and progress toward treatment and cure; general advocacy; and advice regarding food safety and school policies.

Please see our Terms of service and Privacy Policy.

SnackSafely.com, PO Box 141, Hillsdale, NJ 07642

Tag: Dr John Reed

FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...

FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents